1213362-28-7

Basic information

• Product Name: (R)-3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL
• Synonyms: (R)-BETA-(4-CHLOROPHENYL)ALANINOL;(R)-3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL;(gammaR)-gamma-Amino-4-chlorobenzenepropanol;(3R)-3-amino-3-(4-chlorophenyl)propan-1-ol
• CAS NO: 1213362-28-7
• Molecular Formula: C9H12ClNO
• Molecular Weight: 185.65
• Mol File: 1213362-28-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL(1213362-28-7)
• EPA Substance Registry System: (R)-3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL(1213362-28-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 1213362-28-7(Hazardous Substances Data)

Usage

General Description

(R)-3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL is a chemical compound with the molecular formula C9H12ClNO. It is a chiral compound, meaning it has a non-superimposable mirror image. It is a derivative of phenylpropanolamine, which is a sympathomimetic agent that acts as a decongestant and appetite suppressant. The presence of an amino group and a chlorine atom in its structure suggests potential pharmacological and biological activity. (R)-3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL can be used as a building block in the synthesis of various pharmaceuticals and research chemicals. Further research is needed to fully understand its properties and potential applications.

Upstream product

• 19947-39-8 3-amino-3-(4-chlorophenyl)propionic acid 
• 104-88-1 4-chlorobenzaldehyde 
• 131690-60-3 (S)-β-amino-β-(4-chlorophenyl)propionic acid 

Downstream Products

• 1143534-27-3 3-(tert-butoxycarbonylamino)-3-(4-chlorophenyl)propyl Methanesulfonate 
• 1143535-59-4 tert-butyl 1-(4-chlorophenyl)-3-sulfamoylpropylcarbamate 
• 1143535-61-8 3-amino-3-(4-chlorophenyl)propane-1-sulfonamide 
• 1143534-29-5 tert-butyl 1-(4-chlorophenyl)-3-(dimethylamino)propylcarbamate 
• 885672-69-5 1-(4-chlorophenyl)-N³,N³-dimethylpropane-1,3-diamine 
• 1143535-51-6 tert-butyl 1-(4-chlorophenyl)-3-methoxypropylcarbamate 
• 1143535-53-8 1-(4-chlorophenyl)-3-methoxypropan-1-amine 
• 1143532-43-7 4-amino-N-(1-(4-chlorophenyl)-3-(dimethylamino)propyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143533-70-3 (S)-4-amino-N-(1-(4-chlorophenyl)-3-(dimethylamino)propyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143533-52-1 4-amino-N-(1-(4-chlorophenyl)-3-sulfamoylpropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143533-50-9 4-amino-N-(1-(4-chlorophenyl)-3-methoxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 

Relevant articles and documents

Deep learning-driven scaffold hopping in the discovery of Akt kinase inhibitors

Scaffold hopping has been widely used in drug discovery and is a topic of high interest. Here a deep conditional transformer neural network, SyntaLinker, was applied for the scaffold hopping of a phase III clinical Akt inhibitor, AZD5363. A number of nove

Base-induced Sommelet–Hauser rearrangement of N-(α-(2-oxyethyl)branched)benzylic glycine ester-derived ammonium salts via a chelated intermediate

The base-induced Sommelet–Hauser (S–H) rearrangement of N-(α-branched)benzylic glycine ester-derived ammonium salts 1 was investigated. When the α-branched substituent was a simple alkyl, such as a methyl or butyl, desired S–H rearrangement product 2 was obtained in low yield with formation of the [1,2] Stevens rearranged 4 and Hofmann eliminated products 5 and 6. However, when the α-branched substituent had a 2-oxy moiety, such as 2-acetoxyethyl or 2-benzoyloxyethyl, the yields of 2 were improved. These results could be explained by formation of chelated intermediate C that stabilizes the carbanionic ylide, and the subsequent initial dearomative [2,3] sigmatropic rearrangement would be accelerated. The existence of C was supported by mechanistic experiments. This enhancement effect is not very strong or effective; however, it will expand the synthetic usefulness of ammonium ylide rearrangements.

PYRROLO [2,3-D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS

The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I)